Innate Pharma reports encore presentation of TELLOMAK Phase 2 study results

Innate Pharma announced an encore presentation of interim efficacy results from the TELLOMAK Phase 2 study in advanced Mycosis Fungoides according to updated guidelines at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023, being held September 21-23, 2023 in Leiden, the Netherlands. The data confirms clinical activity and favorable safety profile of lacutamab, an anti-KIR3DL2 antibody. The data were previously presented at the 17th International Conference on Malignant Lymphoma, in Lugano (Switzerland), in June 2023. As of March 4, 2022, data cutoff, patients in the KIR3DL2-expressing MF cohort received a median of 4 prior systemic therapies, and had a median follow-up of 12.2 months. In the KIR3DL2 non-expressing cohort, patients received a median of 4.5 prior systemic therapies and had a median follow-up of 13.8 months. Lymph Node assessment is an important component of staging and response assessment in CTCL. In a recent update to the Olsen 2011 guidelines, it was clarified that the pathological assessment of lymph nodes be limited to those that satisfy nodal lymphoma i.e. N3 designation. Based on these criteria, results showed that lacutamab produced an increased global objective response rate of 42.9% in patients with KIR3DL2 greater than or equal to 1% MF, including 2 complete responses and 7 partial responses. Clinical Benefit Rate remained unchanged at 85.7%. In Cohort 3, comprising 18 patients with KIR3DL2 less than 1% MF, findings remain unchanged.